echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Medtronic announces 2021 fiscal year results

    Medtronic announces 2021 fiscal year results

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.



    Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.



    Medtronic’s fourth-quarter revenue in the US market was US$4.



    Medtronic’s 2021 fiscal year announced revenue of 30.



    According to reports, net profit for the 2021 fiscal year is 3.



    Reference source: Medtronic scores European approvals for 2 diabetes management devices

    A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.



    Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.



    Medtronic’s fourth-quarter revenue in the US market was US$4.



    Medtronic’s 2021 fiscal year announced revenue of 30.
    117 billion U.
    S.
    dollars.
    The reported revenue increased by 4%, and the organic growth rate was 2%, which deducted 331 million U.
    S.
    dollars in foreign currency translation gains.
    Including the company's $15 million acquisition of Titan Spine from the Cranial & Spinal Technologies division of Neuroscience's product portfolio.
    Compared with the first quarter of fiscal 2020, the company's earnings from the additional week of the first quarter are approximately $360 to 390 million.


    According to reports, net profit for the 2021 fiscal year is 3.
    606 billion U.
    S.
    dollars, equivalent to 2.
    66 U.
    S.
    dollars per share after dilution.
    The non-GAAP earnings and diluted EPS for the 2021 fiscal year were US$6.
    05 billion and US$4.
    44, respectively, a decrease of 3%.
    According to non-GAAP, diluted earnings per share increased by 2%.
    Operating cash flow for the 2021 fiscal year was US$6.
    24 billion.
    Free cash flow for fiscal 2021 was US$4.
    885 billion, which is equivalent to a free cash flow conversion rate of 81% for non-GAAP net income.
    (Sina Pharmaceutical News)


    Reference source: Medtronic scores European approvals for 2 diabetes management devices

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.